Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials

[1]  G. Lippi,et al.  Statins for Primary Prevention of Cardiovascular Disease. , 2017, Trends in pharmacological sciences.

[2]  A. Hingorani,et al.  Genetic Variants at Chromosome 9p21 and Risk of First Versus Subsequent Coronary Heart Disease Events , 2014, Journal of the American College of Cardiology.

[3]  P. D. de Bakker,et al.  The impact of susceptibility loci for coronary artery disease on other vascular domains and recurrence risk. , 2013, European heart journal.

[4]  U. Laufs,et al.  Beyond statins: what to expect from add-on lipid regulating therapy? , 2013, European heart journal.

[5]  E. Ingelsson,et al.  Multilocus Genetic Risk Scores for Coronary Heart Disease Prediction , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[6]  V. Salomaa,et al.  Genetic Risk Prediction and a 2-Stage Risk Screening Strategy for Coronary Heart Disease , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[7]  F. Van de Werf,et al.  Influence of 23 coronary artery disease variants on recurrent myocardial infarction or cardiac death: the GRACE Genetics Study. , 2013, European heart journal.

[8]  Shah Ebrahim,et al.  Statins for the primary prevention of cardiovascular disease (Review) , 2011 .

[9]  Jemma C. Hopewell,et al.  Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study , 2012, European heart journal.

[10]  J. Danesh,et al.  Large-scale association analysis identifies new risk loci for coronary artery disease , 2013 .

[11]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. , 2012, Lancet.

[12]  R. Collins,et al.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials , 2012, The Lancet.

[13]  A. Hofman,et al.  A genetic risk score based on direct associations with coronary heart disease improves coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC), but not in the Rotterdam and Framingham Offspring, Studies. , 2012, Atherosclerosis.

[14]  A. Peters,et al.  Genetic Markers Enhance Coronary Risk Prediction in Men: The MORGAM Prospective Cohorts , 2012, PloS one.

[15]  N. Sattar,et al.  Genome-Wide Study of Gene Variants Associated with Differential Cardiovascular Event Reduction by Pravastatin Therapy , 2012, PloS one.

[16]  D. Srivastava,et al.  Genetics of Human Cardiovascular Disease , 2012, Cell.

[17]  Udo Hoffmann,et al.  A Genetic Risk Score Is Associated With Incident Cardiovascular Disease and Coronary Artery Calcium: The Framingham Heart Study , 2012, Circulation. Cardiovascular genetics.

[18]  Avis J. Thomas,et al.  Lifetime risks of cardiovascular disease. , 2012, The New England journal of medicine.

[19]  A. D. de Craen,et al.  KIF6, LPA, TAS2R50, and VAMP8 genetic variation, low density lipoprotein cholesterol lowering response to pravastatin, and heart disease risk reduction in the elderly. , 2011, Atherosclerosis.

[20]  S. Leal,et al.  Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. , 2011, Atherosclerosis.

[21]  N. Mehta.  Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. , 2011, Circulation. Cardiovascular genetics.

[22]  Thomas W. Mühleisen,et al.  Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease , 2011, Nature Genetics.

[23]  Thomas J. Wang,et al.  Assessing the Role of Circulating, Genetic, and Imaging Biomarkers in Cardiovascular Risk Prediction , 2011, Circulation.

[24]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[25]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[26]  L. Peltonen,et al.  A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses , 2010, The Lancet.

[27]  M. Sabatine,et al.  Genetic variants in the KIF6 region and coronary event reduction from statin therapy , 2010, Human Genetics.

[28]  J. Catanese,et al.  KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study , 2010, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[29]  F. Van de Werf,et al.  A variant at chromosome 9p21 is associated with recurrent myocardial infarction and cardiac death after acute coronary syndrome: the GRACE Genetics Study. , 2010, European heart journal.

[30]  J. Mega,et al.  Identification of Genetic Variants Associated With Response to Statin Therapy , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[31]  E. Boerwinkle,et al.  The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13) on the effectiveness of statins: the GenHAT study , 2009, Pharmacogenetics and genomics.

[32]  G. Moneta,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[33]  E. Boerwinkle,et al.  Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study , 2008, Pharmacogenetics and genomics.

[34]  S. Kathiresan,et al.  Polymorphisms Associated With Cholesterol and Risk of Cardiovascular Events , 2008 .

[35]  M. Pfeffer,et al.  Association Between ADAMTS1 Matrix Metalloproteinase Gene Variation, Coronary Heart Disease, and Benefit of Statin Therapy , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[36]  M. Sabatine,et al.  Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. , 2008, Journal of the American College of Cardiology.

[37]  C. Lewis,et al.  Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study. , 2007, European heart journal.

[38]  S. Humphries,et al.  Candidate gene genotypes, along with conventional risk factor assessment, improve estimation of coronary heart disease risk in healthy UK men. , 2007, Clinical chemistry.

[39]  M. Sabatine,et al.  Asp92Asn Polymorphism in the Myeloid IgA Fc Receptor Is Associated With Myocardial Infarction in Two Disparate Populations: CARE and WOSCOPS , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[40]  Ralph B D'Agostino,et al.  Risk of complications of pregnancy in women with type 1 diabetes: nationwide prospective study in the Netherlands , 2004, BMJ : British Medical Journal.

[41]  J. LeLorier,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[42]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[43]  G. Lowe,et al.  Interleukin-6-174G>C polymorphism and risk of coronary heart disease in west of Scotland coronary prevention study (WOSCOPS)☆ , 2002 .

[44]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[45]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[46]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[47]  L. Berkman,et al.  Genetic susceptibility to death from coronary heart disease in a study of twins. , 1994, The New England journal of medicine.

[48]  G. Berglund,et al.  Design and feasibility , 1993 .

[49]  G. Berglund,et al.  The Malmo Diet and Cancer Study. Design and feasibility. , 1993, Journal of internal medicine.